Business description: AB Science

AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Number of employees: 36

Sales by Activity: AB Science

Fiscal Period: December 2020 (EUR) 2021 (EUR) 2022 (EUR) 2023 (EUR) 2024 (EUR)

Pharmaceuticals

1.58M 1.61M 958K 970K 1.07M

Executive Committee: AB Science

Manager TitleAgeSince
Chief Executive Officer - 2001-07-10
Director of Finance/CFO - 2009-11-19
Chief Tech/Sci/R&D Officer - 2018-03-31
Corporate Officer/Principal - -

Composition of the Board of Directors: AB Science

Director TitleAgeSince
Chairman - 2001-07-10
Director/Board Member - 2011-09-19
Director/Board Member 64 2021-06-26
Director/Board Member 68 2021-06-26
Director/Board Member - 2021-06-26
Director/Board Member - 2021-06-26

Shareholders: AB Science

NameStocks%Valuation
10.41 %
6,888,610 10.41 % 8 M €
UBS Wealth Management SGIIC SA
0.004684 %
3,100 0.004684 % 3 487 €
NameStocks%Valuation
Friedland Gestion SAS
5.198 %
85,471 5.198 % 33 313 €
NameStocks%Valuation
Friedland Gestion SAS
4.167 %
64,103 4.167 % 20 496 €

Company details: AB Science

AB Science SA

3, avenue George V

75008, Paris

+33 1 47 20 00 14

http://www.ab-science.com
address AB Science(AB)

Specialty & Advanced Pharmaceuticals

Change 5-day change 1-year change 3-year change Capi.($)
+5.17%+0.56%-21.49%-79.91% 78.57M
-1.36%-4.35%+43.61%+4.16% 281B
-0.11%-0.26%+21.98%-14.78% 66.27B
+1.30%+5.71%+2.36%-8.19% 8.24B
-0.03%-1.37%+28.97%+95.97% 8.13B
-1.92%-1.02%-3.55%+1.99% 4.45B
-2.69%-1.42%-24.73%+36.12% 3.71B
+8.33%+2.08%-1.03%+13.01% 3.42B
+1.84%-0.07%+34.65%+31.42% 2.58B
-1.01%-2.64%+4.03%-29.74% 1.92B
Average +0.95%-1.30%+8.48%+5.01% 38B
Weighted average by Cap. -0.96%-4.30%+36.74%+2.92%
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!